急性冠状动脉综合征患者血小板活化标志物的变化及临床意义

为探讨血小板活化指标血小板α颗粒糖蛋白CD6 2P、血小板膜糖蛋白Ⅱb Ⅲa复合物纤维蛋白原受体Pac 1,在冠心病急性冠状动脉综合征 (ACS)患者治疗前后的变化规律 ,采用流式细胞仪 (FCM )及全血单克隆抗体标记法 ,检测 6 6例住院ACS患者〔包括不稳定心绞痛 (UAP)组和急性心肌梗死 (AMI)组〕的外周血中血小板糖蛋白CD6 2P、Pac 1在治疗前后的表达 ;同期以年龄、性别相匹配的健康人 2 2例为对照组。结果 :ACS组的CD6 2P、Pac 1表达率治疗后明显降低 (P <0 .0 1) ,且在治疗前后均明显高于对照组 (P <0 .0 5 )。提示 :ACS患者体内血小板处于高度活化状态 ,血小板活化指标可作为冠心病病情监测的有效指标

Clinical Significance and Variation of CD62P and Pac-1 in Patients with Acute Coronary Syndrome

The aim was to assess clinical significance and variation of CD62P and Pac-1 i n patients wi th acute coronary syndrome (ACS). The alphagranulemembrane protein (CD62P) and P ac-1 from whole-blood samples in 66 patients with ACS on attack or on stable period were measured by FCM and monoc lonal antibody. The 66 patients with ACS including 44 with unstable angina pecto ris (UAP) and 22 with acute myocardial infarction (AMI). Meanwhile age-sex matc hed 22 healthy persons were selected as controls. There were significantly highe r platelet CD62P and Pac-1 expression in patients with ACS on attack than those in controls (P<0.05), but platelet CD62P and Pac-1 expression were signif icantly lower after one month therapy in patients with ACS, but still significan tly higher than controls (P<0.05). It suggests that platelet activation is high in patients with ACS, platelet CD62P and Pac-1 expression can be the effec tive index of monitoring coronary heart diseases.